Search

Your search keyword '"Ducassou, Stephane"' showing total 122 results

Search Constraints

Start Over You searched for: Author "Ducassou, Stephane" Remove constraint Author: "Ducassou, Stephane"
122 results on '"Ducassou, Stephane"'

Search Results

1. AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial

2. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

3. ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

4. Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART

5. Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

7. Antinuclear antibody–associated autoimmune cytopenia in childhood is a risk factor for systemic lupus erythematosus

8. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS

9. The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study

10. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial

11. Risk factors in pediatric Malignant Peripheral Nerve Sheath Tumors (MPNST): Results from the French Pediatric Oncology Society (SFCE) cohort

14. Determinants of long-term outcomes of splenectomy in pediatric autoimmune cytopenias

15. Invasive Fungal Infections in Immunocompromised Children: Novel Insight Following a National Study

16. A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety

17. COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE)

18. Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation

19. ATMgerm line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

20. COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE)

21. Ovarian Function and Spontaneous Pregnancy After Hematopoietic Stem Cell Transplantation for Leukemia Before Puberty: An L.E.A. Cohort Study

23. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

24. Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes

28. Abstract CT088: Phase I/II study of the PARP inhibitor olaparib in combination with irinotecan in children with advanced malignancies: arm D of the AcSé-ESMART trial

29. Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors

32. Securing access to innovative anticancer therapies for children, adolescents, and young adults outside clinical trials: The SACHA study of the French Society of Pediatric Oncology (SFCE).

36. Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement

37. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial

39. A phase 2 study of nilotinib in pediatric patients with CML:Long-term update on growth retardation and safety

40. Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

41. Chromothripsis and Genomic Complexity As Pejorative Prognostic Markers in Pediatric and Adult T-ALL

42. ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

43. Chronic Graft-Versus-Host Disease in Long-Term Survivors of Childhood Leukemia

44. NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

46. Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium

47. Thymus and mediastinal node involvement in childhood langerhans cell histiocytosis: Long-term follow-up from the French national cohort

48. SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers

Catalog

Books, media, physical & digital resources